A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia

Psychiatry Research

Volumn 256, Issue , 2017, Pages 267-274

  Harrow, Martin ^a   Jobe, Thomas H ^a   Faull, Robert N ^a   Yang, Jie ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Employment; Negative symptoms; Outcome; Psychosis; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; JOB ADAPTATION; JOB PERFORMANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; WORKING TIME; CASE CONTROL STUDY; FOLLOW UP; MIDDLE AGED; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME; WORK PERFORMANCE; YOUNG ADULT;

EID: 85021190128     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2017.06.069     Document Type: Article

References (67)

1. Alonso, J., Croudace, T., Brown, J., Gasquet, I., Knapp, M.R., Suárez, D., Novick, D., Health related quality of life (HRQL) and continuous antipsychotic treatment: 3 year results from the schizophrenia health outcomes (SOHO) study. Value Health 12 (2009), 536–543.
2. Barnes, S.S., Badre, N., Is the evidence strong enough to warrant long-term antipsychotic use in compulsory outpatient treatment?. Psychiatr. Serv., 2016.
3. Berridge, K., The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 191 (2007), 391–431.
4. Bland, R., Parker, J., Orn, H., Prognosis in schizophrenia: prognostic predictors and outcome. Arch. Gen. Psychiatry 35 (1978), 72–77.
5. Bleuler, M., The Schizophrenic Disorders: Long-Term Patient and Family Studies. 1978, Yale University Press, New Haven.
6. Bola, J.R., Lehtinen, K., Cullberg, J., Ciompi, L., Psychosocial treatment, antipsychotic postponement, and low dose medication strategies in first episode psychosis: a review of the literature. Psychosis 1 (2009), 4–18.
7. Bond, G.R., Drake, R.E., Becker, D.R., Generalizability of the individual placement and support (ips) model of supported employment outside the US. World Psychiatry 11 (2012), 32–39.
8. Buchanan, R., Kreyenbuhl, J., Kelly, D., Noel, J., Boggs, D., Fischer, B., Himelhoch, S., Fang, B., Peterson, E., Aquino, P., Keller, W., The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36 (2010), 71–93.
9. Buchsbaum, M.S., Potkin, S.G., Siegel, B.V., Lohr, J., Katz, M., Gottschalk, L.A., Gulasekaram, B., Marshall, J.F., Lottenberg, S., Teng, C.Y., Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry 49 (1992), 966–974.
10. Carpenter, W.T. Jr, Sacks, M.H., Strauss, J.S., Bartko, J.J., Rayner, J., Evaluating signs and symptoms: comparison of structured interview and clinical approaches. Br. J. Psychiatry 128 (1976), 397–403.
11. Chouinard, G., Jones, B.D., Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry 137 (1980), 16–21.
12. Ciompi, L., Hoffmann, H., Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic. World Psychiatry 3 (2004), 140–146.
13. Endicott, J., Spitzer, R., A diagnostic interview. Arch. Gen. Psychiat. 35 (1978), 837–844.
14. Fallon, P., Dursun, S., Deakin, B., Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther. Adv. Psychopharmacol. 2 (2012), 13–22.
15. Fenton, W., McGlashan, T., Sustained remission in drug-free schizophrenic patients. Am. J. Psychiatry 144 (1987), 1306–1309.
16. Gilbert, P.L., Harris, M.J., Jeste, D.V., McAdams, L.A., Considering neuroleptic maintenance and taper on a continuum: need for individual rather than dogmatic approach. Arch. Gen. Psychiatry 52 (1995), 209–212.
17. Green, M., What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996), 321–330.
18. Green, M., Kern, R., Braff, D., Mintz, J., Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 26 (2000), 119–136.
19. Hanley, J.A., Negassa, A., Edwardes, M.D., Forrester, J.E., Statistical analysis of correlated data using generalized estimating equations: an orientation. Am. J. Epidemiol. 157 (2003), 364–375.
20. Harding, C., Brooks, G., Ashikiga, T., Strauss, J., Breier, A., The Vermont longitudinal study of persons with severe mental illness: II. long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am. J. Psychiat 144 (1987), 727–735.
21. Harding, C.M., Strauss, J.S., Hafez, H., Lieberman, P.B., Work and mental illness: I. Toward an integration of the rehabilitation process. J. Nerv. Ment. Dis. 175 (1987), 317–326.
22. Harrow, M., Jobe, T., Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multi-followup study. J. Nerv. Ment. Dis. 195 (2007), 406–414.
23. Harrow, M., Jobe, T.H., Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?. Schizophr. Bull. 39 (2013), 962–965.
24. Harrow, M., Goldberg, J., Grossman, L., Meltzer, H., Outcome in manic disorders: a naturalistic followup study. Arch. Gen. Psychiat. 47 (1990), 665–671.
25. Harrow, M., Grossman, L., Jobe, T., Herbener, E., Do patients with schizophrenia ever show periods of recovery?: A 15 year multi-followup study. Schizophr. Bull. 31 (2005), 723–734.
26. Harrow, M., Jobe, T.H., Faull, R.N., Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol. Med. 42 (2012), 2145–2155.
27. Harrow, M., Jobe, T., Faull, R., Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol. Med. 44 (2014), 3007–3016.
28. Healy, D., The Creation of Psychopharmacology. 2002, Harvard University Press.
29. Herbener, E., Harrow, M., Are negative symptoms associated with functioning deficits in both schizophrenic and non-schizophrenic patients? A ten-year longitudinal analysis. Schizophr. Bull. 30 (2004), 813–825.
30. Hollingshead, A., Redlich, F., Social Class and Mental Illness. 1958, John Wiley & Sons, New York.
31. Howes, O.D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., Kapur, S., The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 69 (2012), 776–786.
32. Ioannidis, J.P., Why most published research findings are false. PLoS Med., 2, 2005, e124.
33. Jablensky, A., Sartorius, N., What did the WHO studies really find?. Schizophr. Bull. 34 (2008), 253–255.
34. Jobe, T., Harrow, M., Schizophrenia course, long-term outcome, recovery, and prognosis. Curr. Dir. Psychol. Sci. 19 (2010), 220–225.
35. Johnstone, E.C., Macmillan, J.F., Frith, C.D., Benn, D.K., Crow, T.J., Further investigation of the predictors of outcome following first schizophrenic episodes. Br. J. Psychiatry 157 (1990), 182–189.
36. Jung, E., Wiesjahn, M., Wendt, H., Bock, T., Rief, W., Lincoln, T.M., Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol. Med. Adv. Access, 2016, 10.1017/S0033291716000775.
37. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J.M., Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev., 2012, 5.
38. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J.M., Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet, 2012.
39. Liang, K., Zeger, S., Longitudinal data analysis using Generalized Linear Models. Biometrika 73 (1986), 13–22.
40. McCullagh, P., Nelder, J., Generalized Linear Models. 2nd ed, 1989, Chapman & Hall, New York, NY.
41. McGorry, P., Alvarez-Jimenez, M., Killackey, E., Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 70 (2013), 898–900.
42. McGurk, S.R., Mueser, K.T., Covell, N.H., Cicerone, K.D., Drake, R.E., Silverstein, S.M., Medialia, A., Myers, R., Bellack, A.S., Bell, M.D., Mental health system funding of cognitive enhancement interventions for schizophrenia: summary and update of the New York Office of Mental Health expert panel and stakeholder meeting. Psychiatr. Rehabil. J. 36 (2013), 133–145.
43. Moilanen, J., Haapea, M., Miettunen, J., Jääskeläinen, E., Veijola, J., Isohanni, M., Koponen, H., Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication–A 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur. Psychiatry 28 (2013), 53–58.
44. Moncrieff, J., A critique of the dopamine hypothesis of schizophrenia and psychosis. Harv. Rev. Psychiatry 17 (2009), 214–225.
45. Moncrieff, J., The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment. 2009, Palgrave Macmillan, Basingstoke, UK.
46. Mueser, K.T., Deavers, F., Penn, D.L., Cassisi, J.E., Psychosocial treatments for schizophrenia. Annu Rev. Clin. Psychol. 9 (2013), 465–497.
47. Murray, R.M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., Taylor, D., Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. Br. J. Psychiatry 209 (2016), 361–365.
48. Olfson, M., Blanco, C., Liu, S., Wang, S., Correll, C.U., National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch. Gen. Psychiatry 69 (2012), 1247–1256.
49. Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J.K., Lieberman, J., Barriers to employment for people with schizophrenia. Am. J. Psychiatry 163 (2006), 411–417.
50. Seeman, M.V., Seeman, P., Is schizophrenia a dopamine supersensitivity psychotic reaction?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 48 (2014), 155–160.
51. Seeman, P., Schwarz, J., Chen, J.F., Szechtman, H., Perreault, M., McKnight, G.S., Roder, J.C., Quirion, R., Boksa, P., Srivastava, L.K., Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006), 319–346.
52. Seikkula, J., Alakare, B., Aaltonen, J., The comprehensive open-dialogue approach in western lapland: II. Long-term stability of acute psychosis outcomes in advanced community care. Psychosis 3 (2011), 192–204.
53. Silvestri, S., Seeman, M.V., Negrete, J., Houle, S., Shammi, C., Remington, G.J., Kapur, S., Zipursky, R.B., Wilson, A.A., Christensen, B.K., Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacol. (Berl.) 152 (2000), 174–180.
54. Stefanacci, R.G., Arnicar, R., Clark, T.R., Gerber, J., Haimowitz, D., Kuhlor, A., Scanland, S., Improving the management of disruptive behavior and reducing antipsychotic medications in nursing facility residents. Consult. Pharmacist® 29 (2014), 797–812.
55. Stephens, J., Pascal, R., McHugh, P., Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. J. Nerv. Ment. Dis. 185 (1997), 715–721.
56. Strauss, J., Carpenter, W., The prediction of outcome in schizophrenia: I characteristics of outcome. Arch. Gen. Psychiatry 27 (1972), 739–746.
57. Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., Iyo, M., Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 227 (2015), 278–282.
58. Tandon, R., Belmaker, R., Gattaz, W.F., World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100 (2008), 20–38.
59. Vaillant, G., The prediction of recovery in schizophrenia. J. Nerv. Ment. Dis. 135 (1962), 448–457.
60. Vaillant, G., Prospective prediction of schizophrenic remission. Arch. Gen. Psychiatry 11 (1964), 509–518.
61. Vaillant, G., A 10-year followup of remitting schizophrenics. Schizophr. Bull. 4 (1978), 78–85.
62. Westermeyer, J., Harrow, M., Prognosis and outcome using broad DSM-II and narrow DSM-III concepts of schizophrenia. Schizophr. Bull. 10 (1984), 624–637.
63. Whitaker, R., Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill. 2010, Basic Books, Cambridge, MA.
64. Whitaker, R., Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. 2011, Broadway Books, New York.
65. Wils, R.S., Gotfredsen, D.R., Hjorthøj, C., Austin, S.F., Albert, N., Secher, R.G., Thorup, A.A.E., Mors, O., Nordentoft, M., Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis. Schizophr. Res., 2016.
66. Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial recovery in remitted first-episode psychosis. JAMA Psychiatry 70 (2013), 913–920.
67. Zigler, E., Glick, M., The developmental approach to adult psychopathology. Clin. Psychol. 54 (2001), 2–11.